Viatris Inc.
VTRS
Pozycja w akcjach
#1100
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its... Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Cena akcji
$18.45
Kapitalizacja rynkowa
$21.19B
Zmiana (1 dzień)
1.04%
Zmiana (1 rok)
78.95%
Kraj
US
Handel Viatris Inc. (VTRS)
Kategoria
Healthcare
Wskaźnik P/E dla Viatris Inc. (VTRS)
Wskaźnik P/E na dzień October 2026 TTM: -48.44
Według najnowszych raportów finansowych i ceny akcji Viatris Inc., obecny wskaźnik P/E (TTM) wynosi -48.44. Na koniec 2023 wskaźnik P/E wynosił 237.65.
Historia wskaźnika P/E dla Viatris Inc. od 2004 do 2026
Wskaźnik P/E na koniec każdego roku
| Rok | Wskaźnik P/E | Zmień |
|---|---|---|
| 2026 (TTM) | -48.44 | 106.76% |
| 2024 | -23.43 | -109.86% |
| 2023 | 237.65 | 3,561.56% |
| 2022 | 6.49 | -150.36% |
| 2021 | -12.89 | -23.37% |
| 2020 | -16.82 | -102.51% |
| 2019 | 670.00 | 1,568.83% |
| 2018 | 40.15 | 23.36% |
| 2017 | 32.55 | -21.33% |
| 2016 | 41.37 | 30.38% |
| 2015 | 31.73 | 31.72% |
| 2014 | 24.09 | -12.25% |
| 2013 | 27.45 | 54.35% |
| 2012 | 17.79 | 3.26% |
| 2011 | 17.22 | -13.30% |
| 2010 | 19.86 | -17.85% |
| 2009 | 24.18 | -257.52% |
| 2008 | -15.35 | 544.28% |
| 2007 | -2.38 | -108.19% |
| 2006 | 29.09 | 24.24% |
| 2005 | 23.41 | 28.15% |
| 2004 | 18.27 | 0.00% |
Wskaźnik P/E dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/E | Różnica wskaźnika P/E | Kraj |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -172.16% |
IN
|
Jak odczytywać wskaźnik P/E?
Wskaźnik Cena/Zysk (P/E) mierzy relację między ceną akcji firmy a jej zyskiem na akcję.
Niski, ale dodatni P/E oznacza firmę osiągającą wysokie zyski względem obecnej wyceny i może być niedowartościowana. Wysoki ujemny (bliski 0) P/E wskazuje na duże straty.
Firmy z P/E powyżej 30 lub ujemnym uznaje się zazwyczaj za "akcje wzrostowe", czyli inwestorzy oczekują wzrostu lub przyszłych zysków.
Firmy z dodatnim P/E poniżej 10 uznaje się za "akcje wartościowe", co oznacza, że są już bardzo dochodowe, ale bez dużego potencjału wzrostu.